<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02469597</url>
  </required_header>
  <id_info>
    <org_study_id>12-260B</org_study_id>
    <nct_id>NCT02469597</nct_id>
  </id_info>
  <brief_title>Single Dose of Furosemide to Improve Respiratory Distress in Moderate to Severe Bronchiolitis</brief_title>
  <official_title>Single Dose of Furosemide to Improve Respiratory Distress in Moderate to Severe Bronchiolitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess if administration of an early single dose of a
      diuretic (furosemide) to children with moderate to severe bronchiolitis can reduce
      extravascular lung water in an effort to reduce respiratory rate, retractions, intubations,
      and length of stay.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomization and Blinding:

      Subjects will be randomly assigned by a 1:1 ratio to either furosemide or placebo. The
      Biostatistics Unit will develop a randomization procedure using a permuted block design. The
      randomization will be stratified by mode of delivery of furosemide: IV or PO. Blinding will
      be maintained at all times throughout the study. The only unblinded study personnel will be
      the pharmacy department who will dispense either of placebo or furosemide to each patient.
      Blinding will be broken only in the case of allergic reaction in which case a pediatric
      attending physician, not involved with the study (designated prior to study initiation) will
      be notified to access the intervention of that patient. If such an event should occur, the
      primary investigator and IRB will be notified by e-mail/phone, and an adverse event will be
      documented.

      Materials / Methods:

      All patients aged 0-4 years old with primary diagnosis of bronchiolitis on assessment by the
      Emergency Department will be evaluated for inclusion to study. The goal patient enrollment is
      100 patients, which is required to achieve statistical significance (see below). As this
      study focuses on moderate (admitted) to severe (requiring mechanical ventilation) patients
      with bronchiolitis, further documentation would be completed on a data collection sheet.
      Randomization will occur upon consent to study. In collaboration with the Biostatistics Unit,
      patients will be randomly assigned by a 1:1 ratio to either furosemide or placebo. There will
      be a randomization procedure using a permuted block design. The randomization will be
      stratified by mode of delivery of intervention: IV or PO. The corresponding intervention
      (placebo or furosemide) will then be dispensed by pharmacy for administration in a blinded
      manner by the patient's nurse and/or physician. Either a single dose furosemide (1mg/kg or
      10mg - whichever is less) will be administered orally PO (or intravenously [IV] if IV is
      present), or a placebo of equal volume. Ideally, the intervention dose will be administered
      as early as possible (immediately after decision to admit was made and consent obtained).
      Subsequent retrieval of that data will be done by study personnel. Data recorded on the data
      collection sheet can include: O2 Saturation/Weight (pre-intervention and, 2 and 4 hours
      post-furosemide/control), Age, Gender, Prematurity (&lt;32 weeks gestation), history of
      mechanical ventilation, history of wheeze / asthma, history of furosemide use, interventions
      prior to furosemide (racemic epinephrine, albuterol, or non-invasive ventilation), RSV /
      Influenza status, degree of dehydration (mild / moderate / severe), onset of symptoms prior
      to triage, +/- apnea, timing from initiation of visit until furosemide administration and/or
      non-invasive/invasive ventilator support, and reason for admission to ICU if necessary.

      Considerations for all analyses:

      All analyses will be carried out under the intention to treat principle; patients will be
      analyzed according to the groups to which they were randomized. (However, it is likely that
      the intention to treat population will be the same as the per protocol population.)

      The primary analyses will be carried out for all patients. Mode of delivery of furosemide (IV
      vs. PO) will not be included in the analysis, as the aim of the study is to examine the
      effects of furosemide, regardless of mode of delivery. Randomization will be stratified by
      mode of delivery, so that the distribution of mode of delivery will be the same for the two
      treatment groups. Secondary subgroup analyses will be performed analyzing each mode of
      delivery (IV, PO), separately. These secondary subgroup analyses will be the same as the
      primary analyses.

      Analyses for Specific Aims:

      1. The association between treatment (furosemide) and control (placebo) groups will be
      compared using the chi-square test for the categorical outcomes (25% decrease in respiratory
      rate, intubation, etc).

      Percent change in respiratory rate will be compared using the two sample t-test. If the usual
      assumptions required for the t-test are not met, then either a suitable transformation, or an
      appropriate non-parametric test (the Mann-Whitney test), will be used.

      Length of stay (LOS) will be compared using the Mann-Whitney test. In the event that not all
      participants are followed until discharge from the hospital (in-hospital mortality, not
      discharged by end of study period), survival methods will be used (LOS will be estimated
      using the product-limit method, and the treatment groups will be compared using the log-rank
      test).

      Sample Size Justification:

      Based on clinical experience, we believe that very few patients who are admitted with
      bronchiolitis will have a response (as described in the primary outcome: a decrease in
      respiratory rate of 25% or more, or a return to their age appropriate respiration rate), at 2
      hours post administration of placebo. To be conservative, it is assumed that the response to
      placebo will be no higher than 5%. It is believed that a clinically meaningful response rate
      would be 25% of patients at 2 hours after administration of furosemide. The proposed sample
      size of 49 subjects per group will yield 80% power to detect such a difference using a
      chi-square test with a 0.05 significance level.

      Clinical Outcomes Justification:

      Given the transient nature of bronchiolitis, as symptoms typically peak treatment is sought.
      Along with furosemide's half life of approximately 6hrs, there could be a correlation drawn
      between those children intubated (respiratory failure) or not, as it relates to when
      furosemide was given. Twenty-four hours is a reasonable observation period to correlate to
      the intervention. Intubation beyond that time point may infer that similar treatments of
      furosemide were warranted given the disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Respiratory Rate</measure>
    <time_frame>2 hours after medication adminstration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Respiratory Rate</measure>
    <time_frame>4 hours after medication adminstration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxygen Saturation</measure>
    <time_frame>2 hours after medication adminstration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxygen Saturation</measure>
    <time_frame>4 hours after medication adminstration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Needing Endotracheal Intubation</measure>
    <time_frame>Within 72 hours of medication administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>Participants will be followed for the duration of hospital stay up to 1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Bronchiolitis</condition>
  <arm_group>
    <arm_group_label>Single Dose of Furosemide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Furosemide 1 dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline 1 dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide</intervention_name>
    <description>1 mg/kg intravenous or oral (will give oral unless patient has peripheral IV access in place), maximum dose 10mg (1ml), x 1 dose</description>
    <arm_group_label>Single Dose of Furosemide</arm_group_label>
    <other_name>Lasix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.1ml/kg intravenous or oral (Normal Saline) (will give oral unless patient has peripheral IV access in place), maximum dose 1ml, x 1 dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Acute Bronchiolitis

          -  Admission required per Emergency Department Physician

        Exclusion Criteria:

          -  No legal guardian present

          -  Sulfa allergy

          -  Patient currently on existing diuretic therapy

          -  Tracheostomy

          -  Mild respiratory distress (not requiring admission)

          -  Hypotension / Hemodynamic Instability (defined by age specific criteria at time of
             intervention)

          -  Supplemental Oxygen at home

          -  History of Dialysis / Renal Disease

          -  Those enrolled in another drug interventional study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>48 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandeep Gangadharan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwell Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Steven and Alexandra Cohen Children's Medical Center of New York</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pelletier AJ, Mansbach JM, Camargo CA Jr. Direct medical costs of bronchiolitis hospitalizations in the United States. Pediatrics. 2006 Dec;118(6):2418-23.</citation>
    <PMID>17142527</PMID>
  </reference>
  <reference>
    <citation>Baker MD. Pitfalls in the use of clinical asthma scoring. Am J Dis Child. 1988 Feb;142(2):183-5.</citation>
    <PMID>3341321</PMID>
  </reference>
  <reference>
    <citation>Farias JA, Fernández A, Monteverde E, Flores JC, Baltodano A, Menchaca A, Poterala R, Pánico F, Johnson M, von Dessauer B, Donoso A, Zavala I, Zavala C, Troster E, Peña Y, Flamenco C, Almeida H, Nilda V, Esteban A; Latin-American Group for Mechanical Ventilation in Children. Mechanical ventilation in pediatric intensive care units during the season for acute lower respiratory infection: a multicenter study. Pediatr Crit Care Med. 2012 Mar;13(2):158-64. doi: 10.1097/PCC.0b013e3182257b82.</citation>
    <PMID>21725275</PMID>
  </reference>
  <reference>
    <citation>Hernando Puente M, López-Herce Cid J, Bellón Cano JM, Villaescusa JU, Santiago Lozano MJ, Sánchez Galindo A. [Prognostic factors for bronchiolitis complications in a pediatric intensive care unit]. An Pediatr (Barc). 2009 Jan;70(1):27-33. doi: 10.1016/j.anpedi.2008.08.004. Epub 2008 Nov 25. Spanish.</citation>
    <PMID>19174116</PMID>
  </reference>
  <reference>
    <citation>National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, deBoisblanc B, Connors AF Jr, Hite RD, Harabin AL. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006 Jun 15;354(24):2564-75. Epub 2006 May 21.</citation>
    <PMID>16714767</PMID>
  </reference>
  <reference>
    <citation>Rush MG, Engelhardt B, Parker RA, Hazinski TA. Double-blind, placebo-controlled trial of alternate-day furosemide therapy in infants with chronic bronchopulmonary dysplasia. J Pediatr. 1990 Jul;117(1 Pt 1):112-8.</citation>
    <PMID>2196353</PMID>
  </reference>
  <reference>
    <citation>Stewart A, Brion LP. Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev. 2011 Sep 7;(9):CD001453. doi: 10.1002/14651858.CD001453.pub2. Review.</citation>
    <PMID>21901676</PMID>
  </reference>
  <reference>
    <citation>Hagadorn JI, Sanders MR, Staves C, Herson VC, Daigle K. Diuretics for very low birth weight infants in the first 28 days: a survey of the U.S. neonatologists. J Perinatol. 2011 Oct;31(10):677-81. doi: 10.1038/jp.2011.11. Epub 2011 Mar 10.</citation>
    <PMID>21394079</PMID>
  </reference>
  <reference>
    <citation>Green TP. The pharmacologic basis of diuretic therapy in the newborn. Clin Perinatol. 1987 Dec;14(4):951-64. Review.</citation>
    <PMID>3322632</PMID>
  </reference>
  <reference>
    <citation>Hufnagle KG, Khan SN, Penn D, Cacciarelli A, Williams P. Renal calcifications: a complication of long-term furosemide therapy in preterm infants. Pediatrics. 1982 Sep;70(3):360-3.</citation>
    <PMID>7110808</PMID>
  </reference>
  <reference>
    <citation>Ross BS, Pollak A, Oh W. The pharmacologic effects of furosemide therapy in the low-birth-weight infant. J Pediatr. 1978 Jan;92(1):149-52.</citation>
    <PMID>22591</PMID>
  </reference>
  <reference>
    <citation>Ghanekar AG, Das Gupta V, Gibbs CW Jr. Stability of furosemide in aqueous systems. J Pharm Sci. 1978 Jun;67(6):808-11.</citation>
    <PMID>660463</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2015</study_first_submitted>
  <study_first_submitted_qc>June 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2015</study_first_posted>
  <results_first_submitted>June 30, 2016</results_first_submitted>
  <results_first_submitted_qc>June 30, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 12, 2016</results_first_posted>
  <last_update_submitted>June 30, 2016</last_update_submitted>
  <last_update_submitted_qc>June 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwell Health</investigator_affiliation>
    <investigator_full_name>Sandeep Gangadharan</investigator_full_name>
    <investigator_title>Principal Investigator, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiolitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were enrolled at a tertiary care, academic children’s hospital in the Pediatric Emergency Department from February 2013 to March 2016.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Single Dose of Furosemide</title>
          <description>Furosemide 1 dose
Furosemide: 1 mg/kg intravenous or oral (will give oral unless patient has peripheral IV access in place), maximum dose 10mg (1ml), x 1 dose</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Normal saline 1 dose
Placebo: 0.1ml/kg intravenous or oral (Normal Saline) (will give oral unless patient has peripheral IV access in place), maximum dose 1ml, x 1 dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Dose of Furosemide</title>
          <description>Furosemide 1 dose
Furosemide: 1 mg/kg intravenous or oral (will give oral unless patient has peripheral IV access in place), maximum dose 10mg (1ml), x 1 dose</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Normal saline 1 dose
Placebo: 0.1ml/kg intravenous or oral (Normal Saline) (will give oral unless patient has peripheral IV access in place), maximum dose 1ml, x 1 dose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.7" spread="5.5"/>
                    <measurement group_id="B2" value="8.1" spread="6.8"/>
                    <measurement group_id="B3" value="7.9" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Respiratory Rate</title>
        <time_frame>2 hours after medication adminstration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Dose of Furosemide</title>
            <description>Furosemide 1 dose
Furosemide: 1 mg/kg intravenous or oral (will give oral unless patient has peripheral IV access in place), maximum dose 10mg (1ml), x 1 dose</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline 1 dose
Placebo: 0.1ml/kg intravenous or oral (Normal Saline) (will give oral unless patient has peripheral IV access in place), maximum dose 1ml, x 1 dose</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory Rate</title>
          <units>Percentage change in respiratory rate</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="5.5"/>
                    <measurement group_id="O2" value="-1.7" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Respiratory Rate</title>
        <time_frame>4 hours after medication adminstration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Dose of Furosemide</title>
            <description>Furosemide 1 dose
Furosemide: 1 mg/kg intravenous or oral (will give oral unless patient has peripheral IV access in place), maximum dose 10mg (1ml), x 1 dose</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline 1 dose
Placebo: 0.1ml/kg intravenous or oral (Normal Saline) (will give oral unless patient has peripheral IV access in place), maximum dose 1ml, x 1 dose</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory Rate</title>
          <units>Percentage change in respiratory rate</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="6.5"/>
                    <measurement group_id="O2" value="-5.4" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Oxygen Saturation</title>
        <time_frame>2 hours after medication adminstration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Dose of Furosemide</title>
            <description>Furosemide 1 dose
Furosemide: 1 mg/kg intravenous or oral (will give oral unless patient has peripheral IV access in place), maximum dose 10mg (1ml), x 1 dose</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline 1 dose
Placebo: 0.1ml/kg intravenous or oral (Normal Saline) (will give oral unless patient has peripheral IV access in place), maximum dose 1ml, x 1 dose</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygen Saturation</title>
          <units>Percentage change in oxygen saturation</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.67"/>
                    <measurement group_id="O2" value="0.2" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Oxygen Saturation</title>
        <time_frame>4 hours after medication adminstration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Dose of Furosemide</title>
            <description>Furosemide 1 dose
Furosemide: 1 mg/kg intravenous or oral (will give oral unless patient has peripheral IV access in place), maximum dose 10mg (1ml), x 1 dose</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline 1 dose
Placebo: 0.1ml/kg intravenous or oral (Normal Saline) (will give oral unless patient has peripheral IV access in place), maximum dose 1ml, x 1 dose</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygen Saturation</title>
          <units>Percentage change in oxygen saturation</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="0.58"/>
                    <measurement group_id="O2" value="0.29" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Needing Endotracheal Intubation</title>
        <time_frame>Within 72 hours of medication administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Dose of Furosemide</title>
            <description>Furosemide 1 dose
Furosemide: 1 mg/kg intravenous or oral (will give oral unless patient has peripheral IV access in place), maximum dose 10mg (1ml), x 1 dose</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline 1 dose
Placebo: 0.1ml/kg intravenous or oral (Normal Saline) (will give oral unless patient has peripheral IV access in place), maximum dose 1ml, x 1 dose</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Needing Endotracheal Intubation</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospital Stay</title>
        <time_frame>Participants will be followed for the duration of hospital stay up to 1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Dose of Furosemide</title>
            <description>Furosemide 1 dose
Furosemide: 1 mg/kg intravenous or oral (will give oral unless patient has peripheral IV access in place), maximum dose 10mg (1ml), x 1 dose</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline 1 dose
Placebo: 0.1ml/kg intravenous or oral (Normal Saline) (will give oral unless patient has peripheral IV access in place), maximum dose 1ml, x 1 dose</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Hospital Stay</title>
          <units>Days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="0.5"/>
                    <measurement group_id="O2" value="3.0" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Single Dose of Furosemide</title>
          <description>Furosemide 1 dose
Furosemide: 1 mg/kg intravenous or oral (will give oral unless patient has peripheral IV access in place), maximum dose 10mg (1ml), x 1 dose</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Normal saline 1 dose
Placebo: 0.1ml/kg intravenous or oral (Normal Saline) (will give oral unless patient has peripheral IV access in place), maximum dose 1ml, x 1 dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial was ended early due to recruitment difficulties.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Kristy Williamson</name_or_title>
      <organization>Northwell Health- Cohen Children's Medical Center</organization>
      <phone>718-470-7640</phone>
      <email>kwilliam12@nshs.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

